Table 2.
Univariate and multivariate analysis with respect to 5-year cancer-specific survival
| Variable | Univariate |
Multivariate |
||
|---|---|---|---|---|
| HR | p-value | HR | p-value | |
| Gross (infiltrative/fungating) | 1.87 (1.32–2.66) | < .001 | 1.64 (1.24–2.18) | .001 |
| Stage (III, IV/I, II) | 4.52 (3.26–6.26) | < .001 | 6.30 (4.27–9.29) | < .001 |
| Differentiation (PD/WD, MD) | 3.41 (2.05–5.67) | < .001 | 2.15 (1.27–3.62) | .013 |
| BRAF (mutant/wild type) | 1.92 (1.15–3.19) | .012 | 1.92 (1.11–3.34) | .041 |
| Chemotherapy (treated/not-treated) | 0.94 (0.71–1.25) | .655 | 0.38 (0.28–0.52) | < .001 |
| POSTN (high/low) | 2.00 (1.52–2.64) | < .001 | 1.50 (1.13–2.00) | .006 |
| Tumor location (right/left) | 1.56 (1.19–2.06) | .002 | 1.46 (1.09–1.96) | .011 |
| Tumor-infiltrating lymphocytes (high/low) | 0.69 (0.49–0.97) | .032 | - | .051 |
| Budding (present/absent) | 1.90 (1.36–2.66) | < .001 | - | .129 |
| Crohn-like reaction (present/absent) | 0.71 (0.48–1.06) | .095 | - | .305 |
| Age (≥ 65 yr/< 65 yr) | 1.49 (1.15–1.93) | .003 | - | .053 |
| CIMP (CIMP-H/CIMP-0, L) | 1.91 (1.21–3.02) | .006 | - | .632 |
| Sex (male/female) | 1.04 (0.80–1.36) | .762 | - | - |
| Necrosis (present/absent) | 1.11 (0.70–1.78) | .652 | - | - |
| Serration (present/absent) | 1.42 (0.80–2.54) | .235 | - | - |
| Mucin (present/absent) | 1.32 (0.92–1.90) | .136 | - | - |
| MSI (MSI-H/MSS, MSI-L) | 0.82 (0.48–1.41) | .476 | - | - |
| KRAS (mutant/wild type) | 1.12 (0.84–1.49) | .440 | - | - |
HR, hazard ratio; PD, poorly differentiated; WD, well differentiated; MD, moderately differentiated; POSTN, periostin; CIMP, CpG island methylator phenotype; CIMP-H, CIMP-high; CIMP-L, CIMP-low; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite stable; MSI-L, MSI-low.